Latest Market News

Insurance Australia Group Limited (IAG) has announced a quarterly dividend of AUD 1.5565 per security on its Capital Notes 3, payable mid-March 2026 with partial franking.

Insurance Australia Group Limited has announced a quarterly dividend of AUD 1.6241 per security for its Capital Notes, payable mid-March 2026, reflecting a steady 6.5141% annualised distribution rate.

Insurance Australia Group (IAG) reported a resilient first half of FY26 with an underlying insurance profit of $804 million and maintained its full-year guidance despite integration challenges from the RAC Insurance acquisition.

IAG’s 1H26 results reveal a 35% drop in net profit after tax due to severe weather costs from its RACQI acquisition, yet underlying insurance profit rose 7.6%, supported by solid premium growth and a $200 million share buyback.

Insurance Australia Group Limited has announced a fully franked interim dividend of AUD 0.12 per share for the half-year ending December 2025, alongside a dividend reinvestment plan with no discount.

Insurance Australia Group’s half year net profit fell 35% to $505 million, weighed down by natural peril claims and integration costs from its RACQI acquisition. Despite this, the insurer maintains its full-year guidance and announces a $200 million share buy-back.

EROAD Limited’s CEO Mark Heine has announced his resignation effective June 2026, concluding an 11-year tenure marked by significant company growth across multiple regions.

ANZ Group Holdings Limited reported a robust first quarter with a 75% jump in cash profit, driven by cost cuts and revenue growth, signalling early success in its ANZ 2030 strategy.

Key Petroleum Ltd has raised over A$314,000 through a targeted share placement, aiming to accelerate asset acquisition and maintain existing operations.

Oakridge International Limited has reported a striking turnaround in its half-year results, posting a profit after tax of $172,239 against a prior loss, driven by strong sales and product innovation in healthcare technology.

Empire Resources has successfully raised A$5 million through a two-tranche placement to accelerate exploration at its Yuinmery and Penny’s projects, with strong backing from existing and new investors.

Neuren Pharmaceuticals has initiated a discretionary on-market share buy-back program of up to 5%, citing a strong cash position and undervaluation relative to internal and analyst assessments.